Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastoma

• Main Authors: Kyung‐Nam Koh, Jung‐Man Namgoong, Hee Mang Yoon, Young Ah Cho, Se Hoon Choi, Juhee Shin, Sung Han Kang, Jin Kyung Suh, Hyery Kim, Seak Hee Oh, Kyung Mo Kim, Dae Yeon Kim, Ho Joon Im
• Format: Article
• Language: English
• Published: Wiley 2021-05-01
• Series: Cancer Medicine
• Subjects: CHIC‐HS; hepatoblastoma; pediatric; prognostic factor; PRETEXT
• Online Access: https://doi.org/10.1002/cam4.3897

Abstract Background Prognostic factors in hepatoblastoma need to be reevaluated considering the advances in treatment modalities. The study aimed to evaluate current outcomes of hepatoblastoma and reappraise the association of prognostic factors, including pre‐treatment extent of tumor (PRETEXT) stage with annotation factors and Children's Hepatic tumors International Collaboration‐Hepatoblastoma Stratification (CHIC‐HS) system, with survival outcomes. Methods We evaluated 103 consecutive patients with hepatoblastoma retrospectively according to the treatment period based on the introduction of a liver transplantation program. Results The 5‐year overall survival (OS), event‐free survival (EFS), and transplant‐free survival rates were 80.2%, 74.2%, and 61.8%, respectively. EFS and OS were improved significantly from 58.6% to 81.6% (P = 0.024) and from 58.6% to 90.8% (P < 0.001), respectively, in the late period (N = 74) compared with the early period (N = 29). The PRETEXT stage was significant or marginally significant for EFS and OS in the early period but not in the late period. The P, F, R, and C factors were significant for OS and EFS in the early period. However, in the late period, only the P factor was significant for OS, and the F and M factors were significant for EFS. The CHIC‐HS system was significant or marginally significant for EFS in both the early and late periods; however, it was significant for OS only in the early period. Conclusion Survival rates were significantly improved in children with hepatoblastoma, especially in those with advanced PRETEXT stages with positive annotation factors and in a high‐risk CHIC‐HS group. Prognostic factors had different clinical implications with evolved treatment modalities.